Skip to content

AETERNUM HEALTH, INC.: 10-Q filed 2024-11-14

What AETERNUM HEALTH, INC. reported in its quarterly report filed 2024-11-14 (fiscal Q3 2024): 30 published measures, 91 facts as tagged in accession 0001493152-24-045717.

This filing

Form
10-Q (quarterly report)
Filed
2024-11-14
Fiscal period
fiscal Q3 2024
Accession
0001493152-24-045717 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All AETERNUM HEALTH, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2024-09-3073,033USD
At 2023-12-31308,499USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2024-09-301,609,742USD
At 2023-12-311,534,203USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2024-09-30-1,536,709USD
At 2024-06-30-1,459,514USD
At 2024-03-31-1,343,231USD
At 2023-12-31-1,225,704USD
At 2023-09-30-1,137,340USD
At 2023-06-30-1,194,161USD
At 2023-03-31-892,259USD
At 2022-12-31-1,450,600USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2024-09-300USD
At 2021-12-310USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-77,195USD92
2024-01-01 to 2024-09-30-311,005USD274
2024-04-01 to 2024-06-30-116,283USD91
2024-01-01 to 2024-03-31-117,527USD91
2023-07-01 to 2023-09-30-141,023USD92
2023-01-01 to 2023-09-30-544,584USD273
2023-04-01 to 2023-06-30-301,902USD91
2023-01-01 to 2023-03-31-101,659USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2024-01-01 to 2024-09-30-152,998USD274
2023-01-01 to 2023-09-30-122,488USD273

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2024-07-01 to 2024-09-3015,442USD92
2024-01-01 to 2024-09-3052,779USD274
2023-07-01 to 2023-09-303,676USD92
2023-01-01 to 2023-09-3019,850USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2024-01-01 to 2024-09-30-113,244USD274
2023-01-01 to 2023-09-30486,693USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2024-09-30-2,801,734USD
At 2023-12-31-2,490,729USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2024-07-01 to 2024-09-3048,478,678shares92
2024-01-01 to 2024-09-3048,478,678shares274
2023-07-01 to 2023-09-3047,786,744shares92
2023-01-01 to 2023-09-3040,458,929shares273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2024-07-01 to 2024-09-3048,478,678shares92
2024-01-01 to 2024-09-3048,478,678shares274
2023-07-01 to 2023-09-3047,786,744shares92
2023-01-01 to 2023-09-3040,458,929shares273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2024-07-01 to 2024-09-300USD/shares92
2024-01-01 to 2024-09-30-0.01USD/shares274
2023-07-01 to 2023-09-300USD/shares92
2023-01-01 to 2023-09-30-0.01USD/shares273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2024-07-01 to 2024-09-300USD/shares92
2024-01-01 to 2024-09-30-0.01USD/shares274
2023-07-01 to 2023-09-300USD/shares92
2023-01-01 to 2023-09-30-0.01USD/shares273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-110,084USD92
2024-01-01 to 2024-09-30-308,094USD274
2023-07-01 to 2023-09-30-110,564USD92
2023-01-01 to 2023-09-30-483,086USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2024-09-3072,033USD
At 2023-12-31307,499USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2024-09-30690,061USD
At 2023-12-31501,278USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2024-09-3014,799USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2024-07-01 to 2024-09-3095,200USD92
2024-01-01 to 2024-09-30297,604USD274
2023-07-01 to 2023-09-3094,692USD92
2023-01-01 to 2023-09-30447,449USD273

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2024-09-3034,556USD
At 2023-12-316,876USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-14,884USD92
2024-01-01 to 2024-09-30-10,490USD274
2023-07-01 to 2023-09-30-15,872USD92
2023-01-01 to 2023-09-30-35,638USD273

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2024-07-01 to 2024-09-3028,904USD92
2024-01-01 to 2024-09-3059,246USD274
2023-07-01 to 2023-09-3017,373USD92
2023-01-01 to 2023-09-3050,549USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2024-09-3048,478,678shares
At 2023-12-3148,478,678shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2024-09-30802,692USD
At 2023-12-31802,692USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2024-09-301,000USD
At 2023-12-311,000USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2024-07-01 to 2024-09-3012,045USD92
2024-01-01 to 2024-09-3048,577USD274
2023-07-01 to 2023-09-3034,286USD92
2023-01-01 to 2023-09-30285,463USD273

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2024-07-01 to 2024-09-3032,889USD92
2024-01-01 to 2024-09-30-2,911USD274
2023-07-01 to 2023-09-30-30,459USD92
2023-01-01 to 2023-09-30-61,498USD273

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2024-01-01 to 2024-09-301,956USD274

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2023-01-01 to 2023-09-30660,000USD273

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2024-01-01 to 2024-09-3014,799USD274
2023-01-01 to 2023-09-302,500USD273

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2024-01-01 to 2024-09-3027,680USD274
2023-01-01 to 2023-09-30-3USD273

Inspect the source

Entity
AETERNUM HEALTH, INC. / CIK 0000764630
Captured
2026-09-19T15:02:38.824Z
SEC response SHA-256
6c9d70d4b82a4edc5f4de8082c897762179c66ba1d127e497154b6262edf21b8

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000764630.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))